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Introduction
Tuberculosis remains one of the major causes of death in pa-
tients infected with the human immunodeficiency virus (HIV) 
in resource-limited settings.1 Initiating antiretroviral therapy 
(ART) during the treatment of tuberculosis has been shown to 
reduce mortality across a wide range of CD4+ T-lymphocyte 
(CD4+ cell) counts better than waiting until completion of 
antituberculosis treatment.2 However, in programmes in low-
resource settings, ART uptake is often poor or treatment is 
delayed.3–8 The 2010 revision of the World Health Organization 
(WHO) guidelines for ART in low-resource settings, which 
recommend ART in HIV-positive patients with tuberculosis, 
irrespective of CD4+ cell count, has been a major step forward. 
According to these guidelines ART should be initiated as soon 
as the antituberculosis therapy is tolerated, which could be 
as early as two weeks but ideally not more than eight weeks 
after the start of treatment.9 These revised guidelines were 
followed by the publication of three clinical trials comparing 
early and late ART initiation (2–4 weeks versus 8–12 weeks 
after commencing antituberculosis treatment).10–12 Overall, 
these studies demonstrated that early ART can be safely 
implemented and that it is associated with a survival benefit 
mainly concentrated among individuals with baseline CD4+ 
cell counts of < 50 cells/µL.13
Several factors could preclude the implementation of these 
revised guidelines in routine clinical settings in resource-lim-
ited areas. First, good integration of tuberculosis and HIV care 
programmes, which has proved challenging, is required.14–18 
Operational issues or non-compliance with the guidelines at 
the level of the health care system or provider could delay ART 
initiation.19 Second, the rates of early death and loss to follow-
up before ART initiation are usually higher in programme 
settings than in controlled study settings.6,20–25 Third, early 
initiation in routine care may be delayed by the management 
of co-morbid conditions and opportunistic infections.
Several recent studies have reported the impact of in-
tegrating tuberculosis and HIV services on improved and 
accelerated ART uptake.26–36 However, there has been no 
formal evaluation of the operational feasibility and impact of 
the revised WHO guidelines on the timing of ART initiation 
within routine clinical settings. The main objective of this 
study was to assess the change in time to ART initiation fol-
lowing the implementation of the 2010 WHO ART guidelines 
in a programmatic setting in a resource-limited area. The 
secondary objective was to monitor trends in HIV infection 
treatment outcomes (retention on ART) and toxicity-driven 
antiretroviral drug substitutions. In this operational study, no 
reliable data on the occurrence of the immune reconstitution 
inflammatory syndrome could be obtained.
Methods
Study design and population
In March 2003, Sihanouk Hospital Centre of Hope started 
providing comprehensive HIV care free of charge in Phnom 
Penh, Cambodia, as part of the national ART programme. 
Patients presenting at this nongovernmental hospital come 
from both rural and urban areas (around 50% each) and are 
almost universally poor. We conducted a retrospective cohort 
study with a before–after design. We included in the study all 
ART-naïve HIV-positive adults who initiated antituberculosis 
treatment as inpatients or outpatients over the 18 months that 
preceded and the 18 months that followed the implementa-
tion of the 2010 WHO guidelines in June 2010. The pre-
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implementation period extended from 
1 December 2008 to 31 May 2010 and 
the post-implementation period, from 1 
June 2010 to 30 November 2011. Before 
June 2010 the hospital had followed the 
2006 WHO guidelines.
Organization of tuberculosis and 
HIV care
The tuberculosis and HIV care clinics 
were located within close vicinity of each 
other in the hospital. Over 3000 adult 
patients on ART were in follow-up at the 
HIV clinic; an average of around 1400 
individuals were screened annually for 
tuberculosis at the tuberculosis clinic. All 
patients with HIV infection were routinely 
screened for tuberculosis, and testing for 
HIV was proposed to all cases diagnosed 
with tuberculosis. Details of the organiza-
tional setup are given in Box 1 and Fig. 1.
Tuberculosis screening and 
diagnosis
The tools for tuberculosis diagnosis 
available in our setting included mi-
croscopy to check for acid-fast bacilli 
in sputum smears and lymph node fine 
needle aspirates, chest radiography 
and abdominal ultrasound (Box 1 and 
Fig. 1). Tuberculosis screening and di-
agnostic algorithms recommended by 
the WHO and the national tuberculosis 
programme were used throughout the 
study period.37,38 Tuberculosis was di-
agnosed according to WHO criteria for 
smear-positive pulmonary tuberculosis, 
smear-negative pulmonary tuberculosis 
or extrapulmonary tuberculosis.37,38
All patients diagnosed with tu-
berculosis were evaluated for ART 
eligibility. As explained earlier, up to 
May 2010, the 2006 WHO ART guide-
lines were used;39 following a revision 
of the Cambodian national guidelines 
the 2010 WHO ART guidelines were 
implemented beginning on 1 June 2010. 
Clinicians were instructed to initiate 
ART early on, irrespective of CD4+ 
cell count, and ideally two weeks after 
initiation of antituberculosis treatment.9 
Before implementation, the rationale 
and required changes in patient flow 
and organization were discussed with 
the entire team in charge of tuberculosis 
and HIV services (Box 2).
Antiretroviral initiation and 
monitoring
Programme details, including toxicity 
monitoring and outcome data of the 
ART programme in the Sihanouk Hospi-
tal Centre of Hope have been published 
before (Fig. 1).21,40–43 All medical care 
was provided by physicians, supported 
by a team of nurses and adherence 
counsellors. From early 2010 on, patient 
tracing was reinforced by systematically 
telephoning patients not presenting at 
their scheduled visit. This resulted in 
gradual improvements in outcome 
ascertainment over the study period. 
Patients not presenting at the hospital 
for a period of 6 months without ad-
ditional information were considered 
lost to follow-up.
Data collection
At the onset of the ART programme, 
structured clinical records, data col-
lection tools and a database were 
developed.21 Clinical, laboratory and 
treatment data, including data on tu-
berculosis diagnosis and treatment, were 
collected and stored electronically every 
day. Physicians were trained to conduct 
standardized patient assessment using 
the hospital guidelines and protocols. 
Quality control of the stored data was 
performed at regular intervals. For this 
study, data were extracted from this da-
tabase. Data were cross-checked against 
HIV clinical records and tuberculosis 
registers.
Statistical analysis
The main outcome was the time from 
the diagnosis of tuberculosis to ART 
initiation and the probability of starting 
ART within the 8-week period immedi-
ately following the diagnosis. Secondary 
outcomes included overall programme 
retention (i.e. the proportion of patients 
retained on ART) six months after the 
diagnosis of tuberculosis and the pro-
portion with toxicity-related antiretro-
viral drug substitution six months after 
ART initiation.
Baseline patient characteristics 
before and after implementation were 
described and compared using χ2 or 
Fisher’s exact tests for categorical vari-
ables and the Wilcoxon rank-sum test 
for continuous variables. Follow-up time 
was censored at the earliest of the follow-
ing: ART initiation, death, loss to follow-
up, transfer-out, or end of study period. 
Among individuals initiating ART, we 
calculated the median and interquartile 
Box 1. Overview of care activities at the tuberculosis and HIV care clinics
Tuberculosis clinic
•	 Tuberculosis diagnostic workup (by tuberculosis care physician) of cases referred with 
possible tuberculosis
•	 Immediate referral of tuberculosis cases for HIV testing and same-day enrolment in HIV 
care if HIV-positive
•	 Tuberculosis daily observed treatment and support; monitoring of side-effects
•	 Recording of detailed tuberculosis information (screening, diagnosis, treatment)
HIV clinic
•	 Tuberculosis screening (by HIV care physician)
•	 HIV care programme enrolment (sputum smear microscopy, additional tests as indicated)
•	 Tuberculosis symptom screening at every clinical encounter
•	 Pre-ART initiation (sputum smear microscopy and routine chest X-ray)
•	 IPT if tuberculosis ruled out (since March 2011)
•	 Diagnostic work-up if tuberculosis suspected in HIV-positive individuals (sputum collected 
at tuberculosis clinic)
•	 Tuberculosis treatment decision (HIV care physician with input from tuberculosis physician 
as required)
•	 Electronic recording of clinical information (including on tuberculosis) for all HIV-positive 
individuals
Factors enhancing coordination/integration of tuberculosis and HIV activities
•	 Localized in close vicinity in the same hospital and within the same department
•	 Joint multidisciplinary meetings (logistical, operational, medical topics)
•	 Joint staff trainings
•	 Well defined role of tuberculosis and HIV clinic staff in tuberculosis- and HIV-related activities
•	 Key information on HIV infection and tuberculosis cases collected in a single database
ART, antiretroviral therapy; HIV, human immunodeficiency virus; IPT, isoniazid preventive therapy. 
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range (IQR) of the time in weeks from 
the diagnosis of tuberculosis to ART ini-
tiation before and after implementation 
of the new WHO guidelines, stratified by 
baseline CD4+ cell count. We compared 
pre- and post-implementation values 
using the Wilcoxon test. To visualize 
the effect of guideline implementation, 
we calculated the median ART delay 
per quartile and plotted it on a graph 
(Fig. 2). We used Kaplan–Meier meth-
ods to estimate the cumulative incidence 
of ART initiation at 2, 4 and 8 weeks after 
the diagnosis of tuberculosis among 
those initiating ART. In a secondary 
analysis, we calculated the overall prob-
ability of initiation of ART among all 
individuals diagnosed with tuberculo-
sis, whether or not they ever initiated 
ART. In case of competing risks (ART 
initiation precluded by death), standard 
survival methods can provide biased 
estimates.44,45 Consequently, we used a 
competing risks proportional hazards 
regression model to identify indepen-
dent factors associated with probability 
of ART initiation.44,45 We modelled the 
effect of the implementation of revised 
WHO guidelines on time to ART initia-
tion after a diagnosis of tuberculosis was 
modelled over three time periods: < 2 
weeks, 2–6 weeks and > 6 weeks after the 
diagnosis. In addition, the following fac-
tors were considered for inclusion in the 
model: age, sex, type of tuberculosis (ex-
trapulmonary or pulmonary), point of 
entry into care (HIV or tuberculosis care 
programme) and CD4+ cell count when 
tuberculosis was diagnosed. Starting 
from the full model, a stepwise selection 
process was performed. Associations in 
the model were reported as subhazard 
ratios (sHR). The proportional-hazards 
assumption was tested graphically and 
formally using Schoenfeld residuals. The 
cumulative incidence of starting ART, 
with death before ART (pre-ART death) 
as a competing risk, was calculated as 
well. In sensitivity analysis, we treated 
a combined end-point consisting of 
pre-ART death and loss to follow-up as 
a competing event (i.e. we assumed that 
individuals who were lost to follow-up 
before initiating ART had died).
We performed logistic regression 
to look for an association between 
implementation of the revised WHO 
guidelines and secondary outcomes. Ad-
ditional covariates such as sex, age, body 
weight at the time when tuberculosis 
was diagnosed, type of tuberculosis, and 
point of entry into care were considered 
potential confounders for inclusion. For 
retention on ART as outcome, we se-
lected a priori for inclusion in the model 
the CD4+ cell count and body weight 
at the time of the diagnosis of tubercu-
losis; for drug substitution as outcome, 
we selected a priori sex, age and CD4+ 
cell count at the time of the diagnosis 
of tuberculosis. We analysed the data 
using STATA version 11 (STATACorp 
LP, College Station, United States of 
America). The level of significance was 
set at P < 0.05.
Ethical issues
Since the launch of the HIV care 
programme, clinical data have been 
routinely collected for purposes of 
programme monitoring and evaluation 
and research activities. Patients were 
requested to give written informed 
consent to store and use the data. The 
data collection and informed consent 
procedures were approved by the Insti-
tutional Review Board of the Institute of 
Tropical Medicine, Antwerp, Belgium, 
and the Institutional Review Board of 
the Sihanouk Hospital Centre of Hope.
Results
Patient characteristics
The post-implementation group con-
sisted of 190 patients. Before revised 
guideline implementation, 262 patients 
with tuberculosis and HIV co-infection 
were identified. Both groups were com-
Fig. 1. Organization of tuberculosis and HIV care activities and initiation and 
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Pre-ART counselling: 3 sessions within 2 weeks 
Baseline lab test: FBC, LFT, creatinine, HBV, HCV, 
cryptococcal antigen if CD4+ cell count < 100 per μL
Clinical reevaluation at 1 week of tuberculosis treatment
Clinical reevaluation + tuberculosis treatment response
Check for readiness of ART
Start ART if clinically stable (physician):
-D4T/3TC/EFV (AZT if D4T contra-indicated)
Clinical monitoring (physician):
-Clinical evaluation (Ols, ART and tuberculosis treatment response)
-Toxicity monitoring using standardized data collection tools
-Toxicity grading following WHO guidelines
Schedule: W2, W4, M2, M3, M4, M5, M6 and every 2 months
Adherence: Every visit (counsellor/physician)
Laboratory monitoring:
LTF: W2, W4, M2, M3, M6; CD4, FBC, LTF: every 6 months
If on AZT: Hb at M1, M2, M3; Lactic acid levels on indication
AFB, acid-fast bacilli; AZT, zidovudine; D4T, stavudine; EFV, efavirenz; FBC, full blood count; HBV, hepatitis B 
virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; 3TC, lamivudine; LFT, liver function tests; 
M, month; OI, opportunistic infection; W, week; WHO, World Health Organization.
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parable except that individuals in the 
post-implementation group were older, 
on average, and that a smaller propor-
tion of them were already enrolled in 
HIV care before being diagnosed with 
tuberculosis (Table 1).
Delay to initiation of 
antiretroviral therapy
Among patients initiating ART, the 
median time to ART initiation after the 
diagnosis of tuberculosis declined from 
over 6 weeks before implementation to 
just over 3 weeks after implementation 
(Table 2). Significant decreases in time 
to ART initiation were seen in analysis of 
subgroups based on baseline CD4+ cell 
count, type of tuberculosis, sex and point 
of entry into care. Pre-implementation, 
23% and 65% of individuals initiating 
ART did so by the end of week 4 and 
the end of week 8 after being diagnosed 
with tuberculosis, respectively (Fig. 3). 
These proportions increased to 62% and 
90% after implementation. The post-
implementation period was marked by 
a progressive and sustained decline in 
delay to ART initiation (Fig. 2).
Probability of initiating 
antiretroviral therapy 
We calculated the overall probability of 
starting ART by a certain week for all 
individuals diagnosed with tuberculo-
sis and we treated pre-ART death as a 
competing risk (Table 3). The estimated 
probability of starting ART by weeks 2, 4 
and 8 after the diagnosis of tuberculosis 
increased respectively from 0.8%, 19.5% 
and 58.0% before implementation, to 
3.9%, 51.8% and 78.8% after imple-
mentation. The probability of initiating 
ART by week 8 after the diagnosis of 
tuberculosis, on the assumption that 
individuals lost to follow-up had died, 
was 51.1% and 72.1% pre- and post-
implementation, respectively.
Competing risk regression 
modelling
Both in unadjusted and adjusted analyses, 
the implementation effect was restricted 
to the 2- to 6-week period after the diag-
nosis of tuberculosis, with an adjusted 
sHR of 2.60 (95% CI: 1.87–3.62). We 
found an adjusted sHR of 2.44 when pre-
ART loss to follow-up was considered on 
the assumption that individuals lost to 
follow up had died (Table 4). In addition, 
a CD4+ cell count of ≤ 50 cells/µL and 
enrolment in HIV care before the diag-
nosis of tuberculosis were independently 
associated with an increased probability 
of ART initiation by a given week after 
diagnosis. The delay before ART initiation 
was longer among cases of smear-negative 
pulmonary tuberculosis than among 
cases of extrapulmonary tuberculosis.
Secondary outcomes
Six months after the diagnosis of tuber-
culosis, the proportion of patients who 
had died or were lost to follow-up before 
and after implementation of revised 
WHO guidelines were 24.0% and 24.2%, 
respectively (Fig. 4). The proportion 
retained and on ART increased from 
68% pre-implementation to 73% after 
implementation (adjusted OR: 1.37; 95% 
CI: 0.85–2.19; P: 0.197). The incidence 
of toxicity-driven antiretroviral substi-
tution by the end of the sixth month 
after ART initiation was 10.3% (27/262) 
during the pre-implementation period 
and 11.0% (21/190) in the post-imple-
mentation period (adjusted OR: 1.18; 
95% CI: 0.55–2.18, P-value 0.796). The 
most common adverse reactions were 
hepatitis (17 reports), central nervous 
Box 2. Implementation of early initiation of antiretroviral therapy (ART) in patients 
with tuberculosis and HIV co-infection: organizational aspects
Communication: platforms for discussion, planning and dissemination of information (general)
•	 Weekly medical department meeting (tuberculosis and HIV physicians)
•	 Monthly multidisciplinary meeting of key HIV and tuberculosis care staff to discuss logistical 
and managerial issues
•	 Monthly multidisciplinary operational meeting with the entire HIV and tuberculosis care 
team
•	 Daily educational activities for HIV patients attending the HIV clinic
Preparation of implementation
•	 Required changes in patient flow discussed during above-mentioned meetings: key changes 
consisted of more rapid pre-ART counselling and fast-tracking for ART initiation
•	 No concurrent changes in tuberculosis case-finding strategies or tuberculosis and HIV care 
clinic organizational set-up (staffing, HIV/tuberculosis service delivery model) were made
•	 Starting date of implementation fixed
Monitoring
•	 Within each service, supervisors monitored adherence to the implementation during their 
routine (clinical) work as part of their continuous monitoring of all guidelines and practices
•	 Operational challenges with implementation could be raised by the staff during above-
mentioned team meetings
HIV, human immunodeficiency virus.
Fig. 2. Evolution of time to initiation of antiretroviral therapy (ART), pre- and post-
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IPT, isoniazid preventive therapy; WHO, World Health Organization.
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Table 1. Baseline characteristics of individuals with tuberculosis and HIV co-infection, pre- and post-implementation of the 2010 WHO 
ART guidelines, Cambodia, December 2008 to November 2011
Characteristic Beforea (n = 262) Afterb (n = 190) P
Sex, no. (%)
Female 115 (43.9) 89 (46.8) 0.534
Male 147 (56.1) 101 (53.2)
Age (years), median (IQR) 36 (30.2–41.7) 38 (31.8–44.7) 0.022
≤ 35, no. (%) 125 (47.7) 72 (37.9) 0.038
> 35, no. (%) 137 (52.3) 118 (62.1)
Body weight (kg); (n = 443) 46 (41–52) 46 (40–53) 0.681
> 50, no. (%) 161 (61.9) 119 (65.0) 0.505
≤ 50, no. (%) 99 (38.1) 64 (35.0)
CD4+ cell count (cells/µL) at tuberculosis diagnosis, median (IQR) 59 (18–168) 43 (20.0–162.5) 0.572
> 50, no. (%) 130 (49.6) 82 (43.2) 0.096
≤ 50, no. (%) 104 (39.7) 94 (49.5)
Missing, No. (%) 28 (10.7) 14 (7.4)
Type of tuberculosis, no. (%)
Extrapulmonary 135 (51.5) 92 (48.4) 0.753
Smear-positive pulmonary 55 (21.0) 40 (21.1)
Smear-negative pulmonary 72 (27.5) 58 (30.5)
Enrolled in HIV care before tuberculosis diagnosis, no. (%)
No 107 (40.1) 125 (65.8) < 0.001
Yes 155 (59.2) 65 (34.2)
Initiated on ART, no. (%)
Total 210 (80.1) 152 (80.0) 0.978
Within 6 months after tuberculosis diagnosis 197 (75.2) 151 (79.5) 0.286
ART, antiretroviral therapy; HIV, human immunodeficiency virus; IQR, interquartile range; WHO, World Health Organization.
a December 2008 to May 2010.
b June 2010 to November 2011.
Table 2. Time (weeks) between the diagnosis of tuberculosis and initiation of antiretroviral therapy (ART) pre- and post-
implementation of the 2010 WHO ART guidelines, Cambodia, December 2008 to November 2011
Parameter Median in weeks from tuberculosis diagnosis to ART (IQR)
Before (n = 210) After (n = 152) P
CD4+ cell count (cells/µL) at start of antituberculosis treatment
All 6.3 (4.1–10.0) 3.1 (2.4–5.1) < 0.001
> 50 7.0 (5.3–11.3) 3.6 (2.9–5.3) < 0.001
≤ 50 5.8 (3.7–9.0) 3.0 (2.1–4.4) < 0.001
Sex
Female 6.3 (3.9–10.0) 4.0 (2.6–5.1) < 0.001
Male 5.8 (3.4–9.6) 2.8 (2.0–4.3) < 0.001
Age (years)
≤ 35 3.1 (2.6–5.3) 3.1 (2.1–5.0) < 0.001
> 35 6.1 (3.1–10.0) 3.0 (2.0–4.8) < 0.001
Body weight (kg)
> 50 5.3 (2.8–9) 3.0 (2.0–4.7) < 0.001
≤ 50 6.1 (3.9–9.9) 3.0 (2.0–4.3) < 0.001
Type of tuberculosis
Extrapulmonary 6.7 (4.3–9.9) 3.0 (2.3–4.6) < 0.001
Smear-positive pulmonary 6.6 (4.6–10.0) 3.1 (2.6–4.4) < 0.001
Smear-negative pulmonary 5.6 (3.6–9.8) 4.3 (2.4–5.9) < 0.001
Enrolled in HIV care before tuberculosis diagnosis
No 6.9 (5.1–10.0) 3.0 (2.2–4.8) < 0.001
Yes 5.9 (3.7–10.0) 3.1 (2.0–5.0) < 0.001
HIV: human immunodeficiency virus; IQR, interquartile range; WHO, World Health Organization.
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system toxicity (15 reports) and skin 
rash (10 reports).
Discussion
Clinical trials are pivotal in identifying 
novel therapeutic approaches. However, 
the impact of any approach depends on 
its effective implementation in routine 
clinical services. We assessed the impact 
of the revised WHO guidelines on ART 
initiation after a diagnosis of tuber-
culosis in patients with HIV infection 
attending an urban nongovernmental 
hospital. After implementation of 
the new guidelines, ART delays were 
substantially shortened and initiation 
of ART occurred earlier on average. 
Non-significant increases in retention 
on ART and in ART toxicity were also 
noted. Our findings support the safety 
and feasibility of initiating ART early 
in real-life settings, even in a patient 
population with advanced HIV infec-
tion. To the best of our knowledge, this 
study is among the first formal and 
Fig. 3. Time to initiation of antiretroviral therapy (ART) after diagnosis of tuberculosis, 
pre- and post-implementation of the 2010 WHO guidelines, Cambodia, December 
2008 to November 2011
Weeks since start of TB treatment
Before - CD4+ cells > 50 per μL
After - CD4+ cells > 50 per μL
Before - CD4+ cells ≤ 50 per μL
After - CD4+ cells ≤ 50 per μL
















TB, tuberculosis; WHO, World Health Organization.
Kaplan–Meier graph with data stratified according to CD4+ cell count at time of tuberculosis diagnosis.
Table 3. Overall probability of initiation of antiretroviral therapy (ART) up to week 8 after the diagnosis of tuberculosis, pre- and post-
implementation of the 2010 WHO ART guidelines, by CD4+ cell count and competing risk assumption, Cambodia, December 
2008 to November 2011
CD4+ cell count (cells/µL) Probability of ART initiation, % (95% CI)
At 2 weeks At 4 weeks At 8 weeks
Pre-ART death as competing risk
Pre-implementation
Overall 0.8 (0.1–2.7) 19.5 (14.8–24.8) 58.0 (51.4–64.1)
> 50 0.8 (0.1–3.9) 11.9 (7.1–18.3) 53.4 (44.2–61.7)
≤ 50 1.0 (0.1–5.0) 29.2 (20.5–38.5) 64.2 (53.7–72.9)
Post-implementation
Overall 3.9 (1.7–7.5) 51.8 (44.2–58.9) 78.8 (72.0–84.2)
> 50 0.0 (0–2.8) 45.8 (34.6–56.4) 79.0 (68.1–86.6)
≤ 50 7.6 (3.3–14.2) 60.9 (50.0–70.1) 84.6 (75.3–90.7)
 
Pre-ART death and loss to follow-up as competing risks
Pre-implementation
Overall 0.8 (0.1–2.5) 17.6 (13.2–22.4) 51.1 (44.9–57.0)
> 50 0.8 (0.1–3.8) 11.5 (6.8–17.7) 50.1 (41.9–59.0)
≤ 50 0.9 (0.1–4.7) 26.9 (18.8- 35.7) 58.6 (48.6–67.4)
Post-implementation
Overall 3.6 (1.6–7.1) 47.9 (40.6–54.8) 72.1 (65.1–77.9)
> 50 0.0 (0–4.4) 43.9 (33.0–54.2) 74.4 (63.5–82.5)
≤ 50 7.4 (3.3–13.9) 58.5 (47.9–67.7) 80.8 (71.3–87.5)
CI, confidence interval; WHO, World Health Organization.
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explicit evaluations of these guidelines 
in such settings.
The before–after study design has 
limitations; factors not accounted for 
in the model could have contributed to 
shortening the time to ART initiation. 
Following WHO and national guide-
lines, beginning in March 2011 our pro-
gramme changed its tuberculosis screen-
ing criteria for HIV-positive patients 
and implemented isoniazid preventive 
therapy.46 Concurrent with the national 
scaling-up of ART services, a gradual 
reduction in enrolment of HIV patients 
was seen from early 2009 on, and pro-
portionally fewer cases of tuberculosis 
were diagnosed within the HIV care 
programme after implementation of the 
revised WHO guideline. The overall re-
duced burden of co-infection with HIV 
and tuberculosis and/or the detection 
of tuberculosis at a less advanced stage 
after revised guideline implementation 
could have made it easier to initiate 
ART earlier. However, no waiting lists 
for ART were observed during the 
study period. Furthermore, the overall 
burden of work in the clinics remained 
constant throughout, and patient char-
acteristics were fairly similar before and 
after implementation. It is possible that 
dissemination of the WHO rapid advice 
(November 2009) before the publication 
of the 2010 WHO guidelines sensitized 
HIV and tuberculosis care physicians 
and resulted in their initiating ART ear-
lier before the guidelines were officially 
implemented. Although all these factors 
may have been influential, the rapid and 
sustained reduction in the time to ART 
initiation following implementation of 
the revised WHO guidelines suggests 
that this was the main factor contribut-
ing to the reduction.
An increasing number of studies 
from routine services in resource-limit-
ed settings have reported increased and 
expedited ART uptake,26–35 especially 
after the introduction of a package of in-
terventions aiming at achieving integra-
tion of tuberculosis and HIV care. These 
studies generally precede the 2010 WHO 
ART guidelines. Median ART delays of 
7 and 11 weeks in Uganda and South 
Africa, respectively, were still observed 
after integration in recent studies.29,32 An 
interesting aspect of our study is that 
early ART initiation was implemented 
as a single intervention, without major 
concurrent changes in the tuberculosis/
HIV service delivery model. This makes 
it possible to better quantify the effect 
of the revised guidelines and to demon-
strate their impact when coordination of 
tuberculosis/HIV activities is fairly well 
organized. In this regard, the increase 
we observed in ART initiation by week 
4, from 23% to 62% after the 2010 WHO 
guidelines were implemented, is encour-
aging. As expected, the time between the 
diagnosis of tuberculosis and ART ini-
tiation was shorter for individuals who 
had enrolled in HIV care before being 
diagnosed with tuberculosis. Increased 
HIV testing and enrolment in HIV care 
would also provide opportunities for 
enhanced tuberculosis case-finding 
and prevention through timely ART 
initiation. Since reducing the burden of 
tuberculosis and HIV co-infection will 
require a range of collaborative activities 
Table 4. Competing risk regression modelling of time from the diagnosis of tuberculosis to initiation of antiretroviral therapy (ART) 
among all individuals diagnosed with tuberculosis (n = 452), pre- and post-implementation of the 2010 WHO ART guidelines, 
Cambodia, December 2008 to November 2011
Parameter sHR (95% CI) Adjusted sHRa (95% CI) Adjusted sHR (LTFU = death) 
(95% CI)
Pre-implementation Ref Ref Ref
 
Post-implementation
Time (weeks) from tuberculosis diagnosis 
< 2 0.75 (0.45–1.25) 0.97 (0.57–1.66) 0.76 (0.46–1.23)
2–6 2.45 (1.79–3.65) 2.60 (1.87–3.62) 2.44 (1.79–3.33)
> 6 0.93 (0.59–1.47) 1.08 (0.69–1.69) 1.43 (0.92–2.22)
CD4+ cell count (cells/μL) at tuberculosis 
diagnosis
> 50 Ref Ref Ref
≤ 50 1.46 (1.11–1.91) 1.44 (1.17–1.76) 1.32 (1.07–1.63)
Missing 0.59 (0.23–1.55) 0.26 (0.10–0.66) 0.13 (0.06–0.30)
Type of tuberculosis
Extrapulmonary Ref Ref Ref
Smear-positive pulmonary 1.20 (0.91–1.59) 0.97 (0.73–1.29) 0.87 (0.65–1.15)
Smear-negative pulmonary 0.87 (0.61–1.22) 0.76 (0.59–0.98) 0.77 (0.60–1.00)
Enrolled in HIV care before tuberculosis 
diagnosis
No Ref Ref Ref
Yes 1.16 (0.89–1.52) 1.31 (1.06–1.63) 1.25 (1.00–1.59)
CI, confidence interval; HIV, human immunodeficiency virus; LTFU, loss to follow-up; Ref, reference; sHR, subhazard ratio; WHO, World Health Organization.
a Starting from the full model, a stepwise selection process was followed. Covariates were retained in the model if their removal/inclusion induced a change of > 10% 
in the measure of effect of the main exposure or if they were significantly associated with the outcome in the adjusted analysis.
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involving tuberculosis and HIV services, 
WHO has recently re-emphasized the 
need to provide quality-assured, inte-
grated preventive, diagnostic and treat-
ment services for both tuberculosis and 
HIV infection.47
Several questions remain to be 
explored. Although improved patient 
outcomes have been reported with 
increased and expedited ART uptake,47 
the survival benefit of initiating ART 
early (within 2–4 weeks of tubercu-
losis treatment) for individuals with 
advanced HIV infection has not been 
demonstrated yet in routine practice. 
We observed a non-significant increase 
in patient retention, but since death 
ascertainment among losses to follow-
up improved over time owing to active 
tracing of patients by telephone, mean-
ingful comparison of mortality could 
not be made. Future studies should aim 
for longer patient follow-up and larger 
samples to assess the impact on overall 
patient outcomes. Additional relevant 
information would include data on the 
immune reconstitution inflammatory 
syndrome, drug toxicity associated with 
antituberculosis agents, and treatment 
adherence. We note that ART toxic-
ity occurred frequently over the entire 
study period. Of interest, two recent, 
relatively small clinical trials in Ethiopia 
and Thailand did not show a survival 
benefit with earlier ART initiation.48,49 
How the clinical benefit of initiating 
ART earlier varies across patient popula-
tions and programme settings remains 
to be defined.
After the implementation of the 
revised WHO guidelines, around 30% 
of the individuals with advanced HIV 
infection still initiated ART more than 
4 weeks after being diagnosed with tu-
berculosis. Moreover, many others were 
lost to care soon after the diagnosis and 
before initiating ART, and the same has 
been noted in other programmes.6,20,24 
Additional operational research focus-
ing on the underlying causes of ART 
delay in such patients could reveal the 
programmatic adjustments needed to 
achieve higher rates of early ART initia-
tion. More information on outcomes, 
reasons for early losses to care and pos-
sible barriers to ART would be valuable 
as well.23,50
This study has several limitations. 
They include the retrospective design, 
the use of programme data, and the 
possibility of residual confounding. 
Tuberculosis might have been missed 
or falsely diagnosed in some patients. 
However, the study, which reflects rou-
tine service delivery in resource-limited 
settings, served the purpose of assessing 
operational feasibility and changes in 
ART delay in the period after the imple-
mentation of WHO’s revised guidelines. 
Moreover, it revealed a higher propor-
tion of cases of extrapulmonary tuber-
culosis than other studies. The latest 
WHO recommendations have been 
slightly modified and now allow for ART 
delays beyond 2 weeks in patients with 
less advanced HIV infection.47 The study 
was restricted to a single, well-staffed 
and well-functioning urban hospital 
where HIV and tuberculosis care ser-
vices were hosted on the same premises. 
Consequently, our findings might not 
apply to settings with less coordination 
of tuberculosis and HIV care activities. 
Additional data on operational feasibil-
ity from a wide range of clinical settings 
would be valuable, especially in a con-
text of referrals between ART and tu-
berculosis clinics widely separated from 
each other geographically or in settings 
with poor integration of tuberculosis 
and HIV care services.5,18,47
Conclusion
The implementation of the 2010 WHO 
guidelines on ART initiation in patients 
with tuberculosis was associated with a 
substantial shortening of the time from 
tuberculosis diagnosis to ART initiation 
and with an increased probability of 
ART initiation by week 8 after the tu-
berculosis diagnosis. Additional factors 
associated with a shorter time to ART 
initiation included a baseline CD4+ cell 
count of ≤ 50 cells/µL and enrolment in 
Fig. 4. Patient flowchart and outcomes for tuberculosis patients on antiretroviral 
therapy (ART), 6 months (6M) after the diagnosis of tuberculosis, Cambodia, 









Lost to care: 44 (16.8)
-Died: 9 (3.4)
-LTFU: 35 (13.4)







ART by 6 months:
178 (67.9)
Retained and on
ART by 6 months:
138 (72.6)
Lost to care: 33 (17.4)
-Died: 16 (8.4)
-LTFU: 17 (9.0)




 not yet on




HIV, human immunodeficiency virus; LTFU, lost to follow-up; TB, tuberculosis.
Note: The values in the figure represent absolute patient numbers followed by percentages within 
parentheses. Adult ART-naïve patients with tuberculosis and co-infection with HIV were recruited in the 
18 months before and after the implementation of the 2010 World Health Organization guidelines on 
ART initiation. “Lost to care” refers to patients that either died or were defined as LTFU.
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ملخص
توقيت العلاج بمضادات الفيروسات القهقرية في إحدى مستشفيات كمبوديا بعد تشخيص السل: أثر المبادئ التوجيهية 
المنقحة لمنظمة الصحة العالمية
الغرض  تحديد  ما  إذا  كان  تنفيذ  المبادئ  التوجيهية  لمنظمة  الصحة 
العالمية  لعام  0102  بشأن  بدء  العلاج  بمضادات  الفيروسات 
القهقرية  قد  أدى  إلى  تقليل  التأخير  من  تشخيص  السل  إلى  بدء 
العلاج  بمضادات  الفيروسات  القهقرية  في  إحدى  المستشفيات 
الحضرية في كمبوديا.
الطريقة  تم  إجراء  دراسة  أترابية  استرجاعية  في  مستشفى  غير 
حكومي في بنوم بنه باتباع المبادئ التوجيهية الجديدة لمنظمة الصحة 
العالمية فيما يخص المرضى المصابين بفيروس العوز المناعي البشري 
والسل.  وتم  إدراج  جميع  المرضى  البسطاء  للعلاج  بمضادات 
الفيروسات  القهقرية  والمرضى  الإيجابيين  لفيروس  العوز  المناعي 
البشري  الذين  بدأوا  العلاج  المضاد  للسل  على  مدار  الثمانية  عشر 
شهرًا  السابقة  لتنفيذ  المبادئ  التوجيهية  والتالية  له.  وتم  استخدام 
نموذج ارتداد أخطار تنافسي.
النتائج  بعد  تنفيذ  المبادئ  التوجيهية  لمنظمة  الصحة  العالمية  لعام 
0102،  تم  تحديد  091  مريضًا  إيجابيًا  لفيروس  العوز  المناعي 
البشري  مصابين  بالسل:  35  %  ذكور؛  متوسط  العمر  83  سنة؛ 
متوسط  خط  الأساس  لإحصاء  الخلايا  اللمفاوية  التائية  المساعدة 
(+4DC)  هو  34  خلية/ميكرولتر.  وقبل  التنفيذ،  تم  تحديد 
262 مريضًا؛ 65 % ذكور؛ متوسط العمر 63 سنة؛ متوسط خط 
الأساس لإحصاء الخلايا اللمفاوية التائية المساعدة (+4DC) هو 
95 خلية/ميكرولتر. وعند انخفاض إحصاءات الخلايا اللمفاوية 
التائية  المساعدة  (+4DC)  عند  خط  الأساس  عن  05  خلية/
ميكرولتر، انخفض متوسط تأخير العلاج بمضادات الفيروسات 
القهقرية  من  8.5  أسبوعًا  (النطاق  بين  الشريحتين  الربعيتين: 
من  7.3  إلى  0.9)  قبل  التنفيذ  إلى  0.3  أسابيع  بعده  (النطاق  بين 
الشريحتين  الربعيتين:  من  1.2  إلى  4.4)  (الاحتمال  >100.0)؛ 
إحصاءات الخلايا  اللمفاوية  التائية  المساعدة (+4DC) عند خط 
الأساس <05 خلية/ميكرولتر، انخفض التأخير من 0.7 (النطاق 
بين  الشريحتين  الربعيتين:  من  3.5  إلى  3.11)  إلى  6.3  (النطاق 
بين  الشريحتين  الربعيتين:  من  9.2  إلى  3.5)  أسبوعًا  (الاحتمال 
>100.0). وارتفعت احتمالية بدء العلاج بمضادات الفيروسات 
القهقرية  في  غضون  أربعة  وثمانية  أسابيع  بعد  تشخيص  السل  من 
32 % و56 %،  قبل  التنفيذ  إلى  26 % و09 %  بعده، على  التوالي. 
ولوحظ بعد التنفيذ زيادة غير كبيرة في إبقاء العلاج لمدة الستة أشهر 
والاستعاضة بمضادات الفيروسات القهقرية.
الاستنتاج يؤدي تنفيذ توصيات منظمة الصحة العالمية لعام 0102 
في البيئة السريرية الروتينية إلى اختزال فترة تأخير العلاج بمضادات 
الفيروسات القهقرية. ولابد من إجراء دراسات أوسع ذات متابعة 
أطول لتقييم الأثر على حصائل المرضى.
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Résumé 
Calendrier du traitement antirétroviral dans un hôpital cambodgien après le diagnostic de la tuberculose: impact des lignes 
directrices révisées de l’OMS
Objectif Déterminer si la mise en œuvre des lignes directrices 2010 de 
l’Organisation mondiale de la Santé (OMS) relatives à la mise en œuvre 
du traitement antirétroviral (TAR) a réduit le délai entre le diagnostic de la 
tuberculose et la mise en œuvre du TAR dans un hôpital cambodgien urbain.
Méthodes Une étude de cohorte rétrospective a été effectuée dans 
un hôpital non gouvernemental de Phnom Penh, appliquant les 
nouvelles lignes directrices de l’OMS, auprès de patients atteints du 
virus d’immunodéficience humaine (VIH) et de la tuberculose. Ont été 
inclus tous les patients VIH-positifs, n’ayant pas bénéficié auparavant d’un 
TAR, ayant entamé un traitement antituberculeux au cours des 18 mois 
avant et après la mise en œuvre des lignes directrices. Un modèle de 
régression à risques concurrents a été utilisé.
Résultats Après la mise en œuvre des lignes directrices 2010 de l’OMS, 
190 patients séropositifs atteints de la tuberculose ont été identifiés: 
53% d’hommes; âge médian: 38 ans; nombre médian de lymphocytes 
T CD4+ (cellule CD4+): 43 cellules/µL. Avant la mise en œuvre, 
262 patients ont été identifiés; 56% d’hommes; âge médian: 36 ans; 
nombre médian de cellules CD4+: 59 cellules/µL. Avec un nombre 
médian de cellules CD4+ ≤ 50 cellules/µL, le délai médian avant le TAR 
est passé de 5,8 semaines (intervalle interquartile, IIQ: 3,7 à 9) avant, à 
3.0 semaines (IIQ: 2,1 à 4,4) après la mise en œuvre (P <0,001); avec un 
nombre médian de cellules CD4+ > 50 cellules/µL, le délai est passé de 
7.0 (IIQ: 5,3 à 11,3) à 3,6 semaines (IIQ: 2,9 à 5,3) (P <0,001). La probabilité 
de mise en œuvre du TAR dans les 4 à 8 semaines suivant le diagnostic de 
la tuberculose est passée de 23% et 65%, respectivement, avant la mise 
en œuvre, à 62% et 90% après la mise en œuvre. Une augmentation non 
significative de la rétention à 6 mois et de substitution antirétrovirale a 
été observée après la mise en œuvre.
Conclusion La mise en œuvre des lignes directrices 2010 de l’OMS 
dans un contexte clinique de routine raccourcit le délai avant la mise 
en œuvre du TAR. Des études plus importantes, avec un suivi plus long, 
seront nécessaires pour évaluer l’impact sur les patients.
Резюме
Сроки проведения антиретровирусной терапии в камбоджийской больнице после постановки 
диагноза туберкулеза: влияние нового Руководства ВОЗ
Цель Определить, способствовала ли реализация Руководства 
Всемирной организации здравоохранения по проведению 
антиретровирусной терапии (АРТ) (2010 г.) сокращению 
временной задержки от постановки диагноза туберкулеза до 
проведения АРТ в камбоджийской городской больнице.
Методы Было проведено проспективное когортное исследование 
в негосударственной больнице в Пномпене, в которой 
придерживались нового Руководства ВОЗ при лечении больных 
вирусом иммунодефицита человека (ВИЧ) и туберкулезом. 
В исследование были включены все ВИЧ-положительные 
пациенты, не проходившие курс АРТ, направленные на 
противотуберкулезное лечение в течении 18 месяцев до и после 
реализации Руководства. В исследовании использовалась модель 
регрессии конкурирующих рисков.
Результаты После реализации Руководства ВОЗ от 2010 г. были 
выявлены 190 ВИЧ-положительных пациентов с туберкулезом: 
53% мужчин, средний возраст – 38 лет, среднее исходное 
число CD4+ T-лимфоцитов (клеток CD4+) – 43 клетки/мкл. До 
реализации были выявлены 262 пациента: 56% мужчин, средний 
возрастной показатель – 36 лет, среднее исходное число клеток 
CD4+ – 59 клеток/мкл. При исходном количестве клеток CD4+ 
≤ 50 клеток/мкл., средняя временная задержка до проведения 
АРТ уменьшилась с 5,8 недель (межквартильный диапазон, 
МКД: 3,7–9,0) до реализации Руководства до 3,0 недель (МКД: 
2,1–4,4) после реализации (P < 0,001); при исходном количестве 
клеток CD4+ > 50 клеток/мкл., временная задержка сократилась 
с 7,0 (МКД: 5,3–11,3) до 3,6 (МКД: (2,9–5,3), недель (P< 0,001). 
Вероятность проведения АРТ в течении четырех и восьми 
недель после постановки диагноза туберкулеза повысилась 
с 23% и 65% соответственно (до реализации Руководства ВОЗ 
от 2010 г.), до 62% и 90% соответственно (после реализации). 
После реализации наблюдалось незначительное повышение в 
шестимесячной ретенции.
Вывод Реализация рекомендаций ВОЗ от 2010 г. в обычных 
клинических условиях сокращает временную задержку до 
проведения АРТ. Для оценки влияния на результаты лечения 
пациентов необходимо проведение масштабных исследований 
с длительным периодом наблюдения.
Resumen
La coordinación de la terapia antirretroviral en un hospital camboyano tras el diagnóstico de tuberculosis: el impacto de las 
directrices revisadas de la OMS
Objetivo Determinar si la puesta en práctica de las directrices de la 
Organización Mundial de la Salud (OMS) para el año 2010 acerca de 
la iniciación de la terapia antirretroviral (TAR)redujo la demora desde 
el diagnóstico de tuberculosis hasta el inicio de la TAR en un hospital 
urbano de Camboya.
Métodos Se llevó a cabo un estudio de cohorte retrospectivo en un 
hospital no gubernamental de Phnom Penh que siguió las directrices 
nuevas de la OMS en pacientes con el virus de la inmunodeficiencia 
humana (VIH) y tuberculosis. Se incluyeron todos los pacientes 
seropositivos que no recibieron TAR y que iniciaron un tratamiento contra 
la tuberculosis durante los 18 meses antes y después de la puesta en 
práctica de las directrices. Se utilizó un modelo de regresión de riesgos 
competitivos.
Resultados Tras la puesta en práctica de las directrices OMS para el 
año 2010, se identificaron 190 pacientes seropositivos con tuberculosis: 
el 53% de ellos, varones, edad media de 38 años y un recuento de LT 
CD4+ (células CD4+) como punto de partida con una mediana de 43 
células/µL. Antes de la puesta en práctica, se identificaron 262 pacientes; 
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el 56% de ellos, varones; edad media de 36 años y un recuento de 
células CD4+ como punto de partida con una mediana de 59 células/
µL. Con los recuentos de células CD4+ de ≤ 50 células/µL como punto 
de partida, la demora media hasta la TAR disminuyó de 5,8 semanas 
(rango intercuartílico: 3,7–9,0) antes, a 3,0 semanas (rango intercuartílico: 
2,1–4,4) tras la implementación (P < 0,001); con los recuentos de células 
CD4+ inferiores a 50 células/µL como punto de partida, la demora 
bajó de 7,0 (rango intercuartílico: 5,3–11,3) a 3,6 (rango intercuartílico: 
2,9–5,3) semanas (p < 0,001). La probabilidad de iniciar TAR entre 4 y 8 
semanas tras el diagnóstico de tuberculosis aumentó del 23% y el 65%, 
respectivamente, antes de la implementación, hasta el 62% y el 90% 
después de la misma. Tras la implementación se observó un aumento 
no significativo de la retención a 6 meses, así como de la sustitución 
antirretroviral.
Conclusión La puesta en práctica de las recomendaciones de la OMS 
para el año 2010 en un entorno clínico habitual acorta la demora hasta el 
inicio de la TAR. Son necesarios estudios más amplios con seguimientos 
mayores para evaluar el impacto sobre los resultados en los pacientes.
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